Kliqqo (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate belongs to the calcium‑channel blocker class. It selectively inhibits L‑type calcium channels in arterial smooth muscle, preventing calcium entry that is necessary for contraction. This results in vasodilation of peripheral arteries, decreasing systemic vascular resistance and consequently lowering blood pressure.

Nebivolol hydrochloride is a highly selective β1‑adrenergic receptor antagonist. By blocking β1 receptors in the heart, it reduces heart rate and myocardial contractility, decreasing cardiac output. Additionally, nebivolol stimulates endothelial nitric‑oxide synthase, enhancing nitric‑oxide production and causing further vasodilation, which together contribute to blood‑pressure reduction.

The specific dose of Kliqqo is determined by the prescribing healthcare professional based on the individual’s blood‑pressure profile, comorbid conditions, and response to therapy. Dosage adjustments are made according to clinical judgment and patient tolerance; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety of Kliqqo during pregnancy or lactation has not been established. The potential risks to the fetus or infant must be weighed against the benefits of treating hypertension. It should only be used if the prescriber deems it essential, and alternative therapies with more established safety data may be preferred.

To place an order, submit an enquiry on the Kliqqo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with single‑agent therapies, Kliqqo offers a fixed‑dose combination of a calcium‑channel blocker and a β1‑blocker, providing complementary mechanisms that can achieve greater blood‑pressure control with a single pill. This may improve adherence versus taking two separate tablets. However, clinicians consider individual patient factors, potential drug interactions, and tolerability when selecting between combination therapy and alternative classes such as ACE inhibitors or ARBs.

Kliqqo tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged. No refrigeration is required for this oral solid dosage form.

Kliqqo is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or split unless specifically advised. Consistent timing each day helps maintain stable blood‑pressure control.

The most serious adverse events associated with Kliqqo include severe hypotension, symptomatic bradycardia, hepatic dysfunction, and angioedema. Patients should seek immediate medical attention if they experience fainting, unusually slow heart rate, yellowing of the skin or eyes, or swelling of the face, lips, tongue, or throat. Regular monitoring helps detect these rare but critical reactions early.